435 related articles for article (PubMed ID: 15349909)
1. Effect of high-dose ursodeoxycholic acid on its biliary enrichment in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Hepatology; 2004 Sep; 40(3):693-8. PubMed ID: 15349909
[TBL] [Abstract][Full Text] [Related]
2. Biliary secretion of bile acids and lipids in primary sclerosing cholangitis. Influence of cholestasis and effect of ursodeoxycholic acid treatment.
Stiehl A; Rudolph G; Sauer P; Theilmann L
J Hepatol; 1995 Sep; 23(3):283-9. PubMed ID: 8550992
[TBL] [Abstract][Full Text] [Related]
3. Effect of colitis and ileoanal pouch on biliary enrichment of ursodeoxycholic acid in primary sclerosing cholangitis.
Rost D; Rudolph G; Kloeters-Plachky P; Stiehl A
Dig Dis Sci; 2006 Mar; 51(3):618-22. PubMed ID: 16614977
[TBL] [Abstract][Full Text] [Related]
4. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
[TBL] [Abstract][Full Text] [Related]
5. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
Boberg KM; Schrumpf E
Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
[TBL] [Abstract][Full Text] [Related]
6. [Bile acids in liver diseases--current indications].
Stiehl A
Ther Umsch; 1995 Oct; 52(10):682-6. PubMed ID: 7482380
[TBL] [Abstract][Full Text] [Related]
7. Single or multiple dose ursodeoxycholic acid for cholestatic liver disease: biliary enrichment and biochemical response.
van de Meeberg PC; Wolfhagen FH; Van Berge-Henegouwen GP; Salemans JM; Tangerman A; van Buuren HR; van Hattum J; van Erpecum KJ
J Hepatol; 1996 Dec; 25(6):887-94. PubMed ID: 9007717
[TBL] [Abstract][Full Text] [Related]
8. Cytoprotection with ursodeoxycholic acid: effect in chronic non-cholestatic and chronic cholestatic liver disease.
Lirussi F; Okolicsanyi L
Ital J Gastroenterol; 1992 Jan; 24(1):31-5. PubMed ID: 1571577
[TBL] [Abstract][Full Text] [Related]
9. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
[TBL] [Abstract][Full Text] [Related]
10. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
Rudolph G; Endele R; Senn M; Stiehl A
Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
[TBL] [Abstract][Full Text] [Related]
11. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
[TBL] [Abstract][Full Text] [Related]
12. Prospective evaluation of ursodeoxycholic acid withdrawal in patients with primary sclerosing cholangitis.
Wunsch E; Trottier J; Milkiewicz M; Raszeja-Wyszomirska J; Hirschfield GM; Barbier O; Milkiewicz P
Hepatology; 2014 Sep; 60(3):931-40. PubMed ID: 24519384
[TBL] [Abstract][Full Text] [Related]
13. Treatment of chronic active hepatitis and primary biliary cirrhosis with ursodeoxycholic acid.
Güldütuna S; Leuschner U; Imhof M; Zimmer G
Z Gastroenterol; 1992 Mar; 30 Suppl 1():49-54. PubMed ID: 1449017
[TBL] [Abstract][Full Text] [Related]
14. Primary sclerosing cholangitis and bile acids.
Chazouillères O
Clin Res Hepatol Gastroenterol; 2012 Sep; 36 Suppl 1():S21-5. PubMed ID: 23141889
[TBL] [Abstract][Full Text] [Related]
15. High-dose ursodeoxycholic acid as a therapy for patients with primary sclerosing cholangitis.
Harnois DM; Angulo P; Jorgensen RA; Larusso NF; Lindor KD
Am J Gastroenterol; 2001 May; 96(5):1558-62. PubMed ID: 11374699
[TBL] [Abstract][Full Text] [Related]
16. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice.
Fickert P; Wagner M; Marschall HU; Fuchsbichler A; Zollner G; Tsybrovskyy O; Zatloukal K; Liu J; Waalkes MP; Cover C; Denk H; Hofmann AF; Jaeschke H; Trauner M
Gastroenterology; 2006 Feb; 130(2):465-81. PubMed ID: 16472600
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: ursodeoxycholic acid for primary sclerosing cholangitis.
Triantos CK; Koukias NM; Nikolopoulou VN; Burroughs AK
Aliment Pharmacol Ther; 2011 Oct; 34(8):901-10. PubMed ID: 21883323
[TBL] [Abstract][Full Text] [Related]
18. Ursodeoxycholic acid and methotrexate for primary sclerosing cholangitis: a pilot study.
Lindor KD; Jorgensen RA; Anderson ML; Gores GJ; Hofmann AF; LaRusso NF
Am J Gastroenterol; 1996 Mar; 91(3):511-5. PubMed ID: 8633500
[TBL] [Abstract][Full Text] [Related]
19. Metronidazole and ursodeoxycholic acid for primary sclerosing cholangitis: a randomized placebo-controlled trial.
Färkkilä M; Karvonen AL; Nurmi H; Nuutinen H; Taavitsainen M; Pikkarainen P; Kärkkäinen P
Hepatology; 2004 Dec; 40(6):1379-86. PubMed ID: 15565569
[TBL] [Abstract][Full Text] [Related]
20. Results of a phase I multiple-dose clinical study of ursodeoxycholic Acid.
Hess LM; Krutzsch MF; Guillen J; Chow HH; Einspahr J; Batta AK; Salen G; Reid ME; Earnest DL; Alberts DS
Cancer Epidemiol Biomarkers Prev; 2004 May; 13(5):861-7. PubMed ID: 15159320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
